Alzheimer's disease is a leading cause of severe cognitive decline in older adults. 

It primarily impacts key brain functions, leading to significant difficulties with working memory, language skills, executive functions, attention, and long-term memory.

This disease is characterized by a gradual worsening of both cognitive and overall functional abilities. 

In its early stages, individuals might struggle with complex tasks like driving, experience short-term memory loss, and occasionally exhibit behavioral changes such as anger or aggressiveness. 

As the disease progresses, it often leads to dementia, a hallmark symptom of Alzheimer's and other chronic brain conditions. 

Dementia involves a decline in memory, comprehension, rational thought, language, orientation, emotional control, and judgment. 

Patients in advanced stages of dementia may lose the ability to perform basic daily functions, including talking, using the restroom, eating, and sleeping, and experience such severe memory impairment that they may not recognize their own name or identity. 

With increasing life expectancy in Western countries, the prevalence of Alzheimer's disease is also rising.

While there isn't a known single cause for Alzheimer's disease, several factors increase an individual's risk. 

The most significant risk factor is age; it's most common among the elderly, affecting about one in three people aged 85 or older. 

However, in a small percentage of cases, symptoms can appear as early as the sixth decade of life. 

Other potential contributing factors include vitamin B12 deficiency (common in vegetarians), alcoholism, brain tumors, a family history of the disease, and gender – women face a higher risk than men, possibly due to their longer life expectancy. 

Interestingly, research suggests that a higher level of education may offer some protection against the disease.

Currently, the only treatments approved by the FDA involve medications that prevent the breakdown of the neurotransmitter acetylcholine. 

The brain cells most affected in the early stages of Alzheimer's are those that produce acetylcholine. 

These medications can slow or halt the disease's progression in up to one-third of patients, though they may cause side effects like nausea, vomiting, mild muscle cramps, and sleep problems.

A major hurdle in treating Alzheimer's is the late diagnosis, which typically occurs when as much as 70% of the patient's brain cells have already been damaged.

This delay happens because the brain can often maintain normal function even with extensive neural damage, meaning neither the affected individual nor their family may suspect a problem until much later.

This treatment uses magnetic stimulation to target brain structures and networks linked to the disease, leading to notable improvement for patients.

A BrainsWay safety study on healthy individuals indicated that Deep TMS therapy, unlike standard TMS, had a positive impact on spatial memory in several standard tasks.

These effects were observed after Deep TMS Therapy was applied to deep prefrontal cortical regions. BrainsWay plans to further investigate the effects of stimulation on other brain areas as well.

You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.

However, BrainsWay Deep TMS™ has received the European CE Mark for the treatment of many conditions.

This significant approval underscores the therapy's established safety and efficacy for these indications in Europe. While regulatory statuses vary by region, this CE Mark highlights the recognized potential of Deep TMS as a therapeutic option for:

Major Depressive Disorder (MDD)

Anxiety Depression

Obsessive-Compulsive Disorder (OCD)

Smoking Cessation

Alzheimer's Disease (AD)

Autism

Bipolar Disorder

Chronic Pain

Multiple Sclerosis (MS)

Parkinson's Disease

Post-Stroke Rehabilitation

Post-Traumatic Stress Disorder (PTSD)

Negative Symptoms of Schizophrenia